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Seoul, Republic of KoreaObjectives This study sought to evaluate the relationship between post-stent strut apposition and
follow-up strut coverage using contour plot optical coherence tomographic analysis.
Background Tracking the fate of interested regions of struts at different time points has not been
investigated.
Methods Post-intervention and 6-month follow-up optical coherence tomographic evaluations were
performed in 82 patients treated with biolimus- (n ¼ 37) or sirolimus-eluting stents (n ¼ 45). Post-stent
apposition was classiﬁed as embedded, apposed, or malapposed. For volumetric stent evaluation, the
post-intervention strut-artery distance and the neointimal thickness at follow-up were measured as a
function of the circumferential arc length and longitudinal stent length. Computer-generated contour
plots of the strut-artery distance and neointimal thickness were compared.
Results The percentages of embedded and malapposed struts after intervention were 1.8%
(Interquartile range [IQR]: 0.6% to 6.2%) and 2.3% (IQR: 0.5% to 5.2%), respectively. The percentages of
uncovered and malapposed struts at 6 months were 16.0% (IQR: 7.4% to 33.3%) and 0% (IQR: 0% to
0.7%), respectively. The percentage of uncovered struts at 6 months varied signiﬁcantly with post-stent
strut apposition (0% [IQR: 0% to 11.4%] in embedded, 16.3% [IQR: 8.1% to 31.3%] in apposed, and
26.8% [IQR: 0% to 56.3%] in malapposed, p < 0.001 for all pairwise comparisons). In lesions without
tissue prolapse, embedded struts were all covered (100% covered struts) compared with those with
tissue prolapse (76.8% covered, p < 0.001).
Conclusions The optical coherence tomography–guided optimization of stent strut apposition
enhances strut coverage at follow-up. This comprehensive method for evaluating strut apposition may
provide more useful information to understanding the serial changes in strut coverage. (Neointimal
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642The drug-eluting stent (DES) is a standard modality to
treat patients with symptomatic coronary artery disease.
However, incomplete neointimal coverage is regarded as
an important pathological parameter of late stent thrombosis
in patients treated with DES implantation (1,2). In particular,
it has been demonstrated that following DES implantation,
there was a greater prevalence of malapposed and uncovered
struts leading to increased risk of late stent thrombosis (3,4).
Stent strut apposition and the serial change of neointimal
formation in cross-sectional images of implanted stents
have previously been evaluated by intravascular ultrasound
(IVUS) (5,6). Recently, optical coherence tomography
(OCT) has been used as a powerful high-resolution imaging
modality that can provide more detailed information on
vascular responses to DES versus IVUS (7–9). Although
OCT can more accurately detect minimal neointimal
coverage over the struts, it is still difﬁcult or even impossible
to compare struts between 2 time points (7,10,11). Recently,
contour plot OCT reconstruction was successfully used for
assessing the spatial distribution pattern of strut coverage
and stent malapposition at the strut level (12). This tech-Abbreviations
and Acronyms
CSA = cross-sectional
area(s)
DES = drug-eluting stent(s)
IVUS = intravascular
ultrasound
NIH = neointimal hyperplasia
OCT = optical coherence
tomographynique is also able to visualize both
the gap between the underlying
artery wall and the stent struts
after intervention and the neo-
intimal coverage at follow-up in
the circumferential and longitu-
dinal directions. The objective of
this study was to investigate the
relationship between post-stent
strut apposition and 6-month
follow-up strut coverage using
contour plot OCT analysis.Methods
Study design. A total of 82 stents in 82 patients (37
biolimus A9-eluting stents [Nobori, Terumo Corpora-
tion, Tokyo, Japan] and 45 sirolimus-eluting stents
[Cypher, Cordis Corp., Miami Lakes, Florida]) were
selected from 120 patients enrolled in a randomized trial
comparing the strut coverage of the biolimus A9-eluting
and sirolimus-eluting stents by an optical coherence to-
mography analysis (13). Thirty-eight stents were excluded
for the following reasons: follow-up angiogram was not
performed (n ¼ 7); the OCT catheter could not be
advanced through the lesion due to severe angulation
(n ¼ 5); poor image quality in patients (n ¼ 8); recon-
struction of contour plots image was not possible in
patients due to severe motion artifacts (n ¼ 12); and
mismatch of the contour plots between post-intervention
and follow-up (n ¼ 6). OCT examination was performed
after the procedure and at a 6-month follow-up. Inclusionand exclusion criteria for this study were provided in a
previous study (13). This study was approved by the
institutional review board of our institution, and written
consent was obtained from all enrolled patients.
OCT imaging and analysis. OCT imaging of the target
lesion was performed after the procedure and at the 6-
month follow-up using a frequency-domain OCT system
(C7-XR OCT imaging system, LightLab Imaging, Inc.,
St. Jude Medical, St. Paul, Minnesota) developed to
generate frames at much higher rates and faster pullback
speeds compared with those of time-domain OCT. In
this study, OCT cross-sectional images were generated at
a rate of 100 frames/s, whereas the ﬁber was withdrawn at
a speed of 20 mm/s within the stationary imaging sheath.
A continuous, nonocclusive contrast-saline mixture was
ﬂushed through a guiding catheter at a rate of 4 to 5 ml/s
for 3 to 4 s. During OCT image acquisition, the OCT
catheter was placed as close as possible to a similar location
on 6-month follow-up based on the post-intervention
image to reduce the difference of the acquired OCT im-
ages between 2 time points. All OCT images were ana-
lyzed at a core laboratory (Cardiovascular Research Center,
Seoul, Korea) by analysts who were blinded to patient and
procedural information.
Cross-sectional OCT images were analyzed at 0.2-mm
intervals. A strut was deﬁned as an embedded strut if the
endoluminal strut boundary was below the level of luminal
surface (14). An apposed strut was deﬁned as a strut
completely attached to the vessel wall without any gap
between itself and the wall. A malapposed strut was
deﬁned as a strut that had detached from the vessel wall
by 130 mm (biolimus A9-eluting stent) or 160 mm
(sirolimus-eluting stent) (15,16). Stent and luminal cross-
sectional areas (CSAs) were measured; neointimal hyper-
plasia (NIH) CSA was calculated as the stent CSA minus
the luminal CSA. NIH thickness was measured as the
distance between the endoluminal surface of the neointima
and the strut (17). An uncovered strut was deﬁned as
having an NIH thickness of 0 mm (17). The percentage of
uncovered or malapposed struts was calculated as the ratio
of uncovered or malapposed struts to total struts in all
OCT cross sections. Stent malapposition was further
classiﬁed into persistent, resolved, or late acquired by
comparing the post-procedure and follow-up OCT images
(18). To evaluate the magnitude of malapposition, the
maximal extra-stent lumen CSA and the distance between
the malapposed strut and the vessel wall (the strut-artery
distance) were measured. In addition, tissue prolapse was
deﬁned as a mass protruding into the lumen (more than
250 mm at the thickest point).
Volumetric OCT assessment of stent strut apposition using a
contour plot. Post-intervention and follow-up contour
plot analyses were used to compare vascular responses as
Figure 1. Data Collection Method for Creating Post-Intervention and Follow-Up Contour Map
Measurements of artery-strut distance post-intervention (A) and neointimal hyperplasia (NIH) thickness at 6 months (B) were performed as a function of
circumferential arc length and longitudinal stent length from frames with 0.2-mm intervals.
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643previously described (12). Brieﬂy, the post-intervention
strut-artery distance and NIH thickness over the entire
stent at follow-up were measured as a function of cir-
cumferential arc length and longitudinal stent length from
frames with 0.2-mm intervals (Fig. 1). At the post-
interventional period, individual stent struts were divided
as apposed, malapposed, embedded (with and without
tissue prolapse), or side-branch. At the follow-up, stents
were classiﬁed as uncovered, malapposed, or side-branch
(Fig. 2). The post-interventional strut-artery distance was
measured as a negative value. At follow-up, covered struts
had a positive NIH thickness value, whereas the uncov-
ered-malapposed struts had a negative value. Finally, the
status of post-stent struts (i.e., embedded, apposed, or
malapposed) were monitored and matched as covered, un-
covered, or malapposed at the follow-up. See Figure 3 for
representative contour plots. To compare the status of
struts between the post-intervention and follow-up con-
tour plots, the 2 plots are coregistered based on the
location of a side branch as follows. First, the post-
intervention contour plot is selected as the reference. Sec-
ond, the pattern of stent structure is compared after the
remaining follow-up contour plot is spatially registered to
align with the reference by shifting arc length to match
the location of a side branch at the 2 plots and for the
vessel without side branches. Finally, the status of DES
struts is quantitatively analyzed. To show the accuracy of
the coregistration of the 2 contour plots, we calculated
the averages and standard deviations of the total arclength values, which are used to generate the plots at both
post-intervention and follow-up, and the difference of the
values is then assessed (Fig. 4). Here, SD shows how
much the stent structure is distorted at a single time
point and the average difference represents the accuracy
of coregistration of the contour plots between post-
intervention and follow-up.
Coronary intervention and quantitative coronary angio-
graphy analysis. All patients received at least 75 mg of
aspirin and a loading dose of 300 mg of clopidogrel at least
12 h before percutaneous coronary intervention. Unfractio-
nated heparin was administered to maintain the activated
clotting time >250 s. All percutaneous coronary inter-
ventions were performed according to current standard
techniques. Post-procedure, dual antiplatelet therapy of
100 mg/day aspirin and 75 mg/day clopidogrel was pre-
scribed for 12 months.
Quantitative coronary angiography analysis was per-
formed before and after stent implantation and at follow-up
using an off-line quantitative coronary angiographic system
(CASS system, Pie Medical Instruments, Maastricht, the
Netherlands) in an independent core laboratory (Cardio-
vascular Research Center). Using the guiding catheter for
magniﬁcation calibration, reference vessel diameter and
minimal luminal diameter were measured from diastolic
frames in a single, matched view showing the smallest
minimal luminal diameter. Late loss was deﬁned as the
difference between the post-procedure and follow-up min-
imal luminal diameters.
Figure 2. Typical Examples of Cross-Sectional Optical Coherence Tomographic Images
(A) Most of stent struts are well-apposed post-intervention (white arrows), whereas a smaller portion of them were covered (yellow arrows) or uncovered
(red arrows) at the 6-month follow-up. (B) Some of stent struts were malapposed post-intervention (white arrows) and are uncovered (yellow arrows) at 6-month
follow-up. (C) Some of stent struts are embedded without tissue prolapse post-intervention (white arrows) and are completely covered (yellow arrows) at the
6-month follow-up. (D) Some of stent struts were embedded with tissue prolapse post-intervention (white arrows) and were uncovered (yellow arrows) at the
6-month follow-up.
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644Statistical analysis. Categorical data are presented as
numbers (percentages) and compared with chi-square sta-
tistics or Fisher’s exact test. Continuous data are presented as
mean  SD or median (interquartile range) and compared
using the paired t test. If the distributions were skewed, a
nonparametric test was used. To avoid problems associated
with sample size inﬂation and correlated data, patients with
only 1 target lesion were included for the study. Cross-
section or strut-level analysis was not straightforward
because struts congregate within each lesion under each
individual. For this analysis, multilevel regression model
was applied with random effects within the patient level
because of the clustering nature of data (13). Speciﬁcally,
we used Friedman’s test for the comparisons according to
the status of post-stent struts and Wilcoxon’s rank sum
test for the comparisons according to the stent type and
tissue prolapse (Online Table 1). The signiﬁcance of post-
stent struts status was decided by comparing multilevel
models with the variable to a null model. Then, we estimated
the effect of embedded and malapposed struts compared with
apposed struts (Online Table 1). Interactions between the
variables were not included in the model because none ofthem was signiﬁcant. Statistical analysis was performed with
the Statistical Analysis System software (SAS, version 9.1.3,
SAS Institute, Cary, North Carolina). A value of p < 0.05
denoted statistical signiﬁcance.
Results
Baseline clinical and angiographic ﬁndings of the 82 enrolled
patients are summarized in Table 1. The mean follow-up
period was 185  13 days. Post-intervention and follow-up
OCT procedures were performed in all patients with no
complications or adverse events. OCT data are shown in
Table 2. The percentage of embedded struts after inter-
vention was 1.8% (IQR: 0.6% to 6.2%). Interobserver and
intraobserver variability for embedded struts in this study
were k ¼ 0.975 and k ¼ 0.972 in randomly selected 40 cross
sections with 481 struts. The percentage of malapposed struts
was signiﬁcantly reduced at 6 months (post-procedure: 2.3%
[IQR: 0.5% to 5.2%], follow-up: 0% [IQR: 0% to 0.7%],
p < 0.001). The median NIH thickness and NIH CSA
were 48 (35, 74) mm and 0.2 (0.1, 0.3) mm2, respectively.
The percentage of uncovered struts was 16.0% (IQR: 7.4%
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645to 33.3 %). Cross sections with a ratio of uncovered to total
struts >0.3 was 21.5% (IQR: 6.8% to 49.7%).
Using a computer-generated contour plot, the serial
quantitative analysis of embedded, apposed, and malap-
posed struts after intervention showed a signiﬁcantly
different pattern of stent strut coverage (the percentage of
uncovered struts; 0% [IQR: 0% to 11.4%] in embedded,
16.3% [IQR: 8.1% to 33.3%] in apposed, and 26.8% [IQR:
0% to 56.3%] in malapposed struts, p < 0.001 for all
pairwise comparisons). Particularly, in lesions without tis-
sue prolapse, embedded struts were all covered (100%
covered struts) in comparison to those with tissue prolapse
(76.8% covered, p < 0.001) (Table 3). Typical examples are
shown in Figure 5. Comparing the same malapposed struts
at post-intervention to follow-up showed that 95% of the
acute strut malapposition cases were classiﬁed as resolved at
follow-up, and late acquired malapposition developed in
0.6% of the initially well-apposed struts. There was a lower
tendency in the percentage of uncovered struts at 6 months
in biolimus-eluting stents (13.6% [IQR: 6.6% to 23.4%] vs.
20.7% [IQR: 8.6% to 35.8%] in sirolimus-eluting stents,
p ¼ 0.06]. In biolimus-eluting stents, the percentage of
uncovered struts at 6 months was 0% (IQR: 0% to 3.3%) in
embedded, 14.8% (IQR: 5.7% to 29.0%) in apposed, andFigure 3. Representative Contour Plot Images Post-Intervention and at Follow-Up
(A) Baseline plot of artery-strut spacing post-intervention. Malapposed and embedded
the artery-strut distance post-intervention (range 0.0 to –0.7 mm). (B) The neointimal c
in a 3.0  18-mm biolimus-eluting stent; uncovered struts and struts crossing over
Grayscale indicates a stent strut coverage thickness range of –0.1 to 0.6 mm. (C) At a s
intervention turns into an uncovered strut at follow-up without malapposition (red
6.0 mm from the distal stent margin, an embedded strut becomes a covered strut (gre
a malapposed strut post-intervention becomes a covered strut without malappositio25.0% (IQR: 0% to 50.0%) in malapposed struts (apposed
vs. embedded, p ¼ 0.002; apposed vs. malapposed, p <
0.001). In sirolimus-eluting stents, the percentage of un-
covered struts at 6 months was 0% (IQR: 0% to 17.3%) in
embedded, 21.1% (10.0%, 32.9%) in apposed, and 29.2%
(IQR: 0% to 58.3%) in malapposed struts (apposed vs.
embedded, p ¼ 0.018; apposed vs. malapposed, p ¼ 0.010).
The representative contour plot images of both the biolimus-
and sirolimus-eluting stents are provided in Figure 6. The
mean of average difference of the total arc length values
between post-intervention and follow-up is 0.16  0.08 mm
(Fig. 4). It is more than 0.7 mm in 6 excluded cases with
mismatch of the contour plots between post-intervention
and follow-up.
Discussion
This is the ﬁrst study to evaluate the impact of post-inter-
vention strut apposition on strut coverage at follow-up using
contour map OCT analysis, which enables the serial tracking
of speciﬁc regions of interest of stent. The present analysis
provides an intuitive understanding of the sequential neo-
intimal healing process after stent implantation. This study
demonstrates that embedded and apposed struts afterstruts are indicated with red and green circles, respectively. Grayscale indicates
overage at follow-up as a function of circumferential arc length and stent length
the side branches are indicated with blue and orange circles, respectively.
tent length of 13.6 mm from the distal stent margin, a malapposed strut at post-
arrows on contour plots and cross sections) in A and A0 . At a stent length of
en arrows) in B and B0 . At a stent length of 4.6 mm from the distal stent margin,
n at follow-up (blue arrows) in C and C0 .
Figure 4. Coregistration of 2 Contour Plots Between Post-Intervention and Follow-Up
The 2 plots of post-intervention and follow-up are coregistered based on the location of a side branch. To show the accuracy of the coregistration of the
2 contour plots, average differences were 0 mm (A) and 0.38 mm (B), respectively.
Table 1. Baseline Clinical and Angiographic Characteristics (N ¼ 82)
Age, yrs 63.0  9.1
Male 59 (72.0)
Acute coronary syndrome 15 (18.3)
Hypertension 48 (58.4)
Diabetes mellitus 23 (28.0)
Dyslipidemia 57 (69.2)
Current smoking 16 (19.5)
Previous myocardial infarction 9 (11.2)
Target vessel
Left anterior descending artery 54 (65.9)
Left circumﬂex artery 12 (14.6)
Right coronary artery 16 (19.5)
Lesion length, mm 16.5  4.8
Multivessel disease 39 (47.6)
Type of stent
Biolimus-eluting stent 35 (42.7)
Sirolimus-eluting stent 47 (57.3)
Stent diameter, mm 3.2  0.3
Stent length, mm 18.9  4.4
Maximal inﬂation pressure, atm 15.1  3.2
Reference vessel diameter, mm 3.1  0.4
Pre-intervention minimal lumen diameter, mm 1.2  0.4
Post-intervention minimal lumen diameter, mm 2.8  0.4
Follow-up minimal lumen diameter, mm 2.6  0.5
Late loss, mm 0.3 (0.02–0.50)
Values are mean  SD, n (%), or median (interquartile range).
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646intervention had a higher rate of stent strut coverage at 6
months than was observed in malapposed struts. Particu-
larly, embedded struts, compared with apposed struts,
improved strut coverage. Based on these results, OCT-
guided procedural optimization of stent strut apposition can
enhance the strut coverage.
Because the incomplete re-endothelialization and stent
strut coverage were reported to be associated with late stent
thrombosis after DES implantation (19), there have been
numerous attempts to evaluate the status of stent struts
after intervention and at follow-up by both IVUS and
OCT imaging. Using IVUS to evaluate strut status is
limited due to the innate low resolution of the technique. A
previous study (7) clearly demonstrated the limitations of
IVUS resolution by directly comparing the rate of strut
coverage assessed by OCT versus IVUS in the same set of
stents (25.8% with IVUS vs. 99.9% with OCT). The
advent of 3-dimensional OCT reconstructions allows for
the visualization of the microstructure of coronary arteries
in patients. However, when using current OCT analysis
methods, it remains challenging to compare speciﬁc regions
of struts between baseline and follow-up with serial OCT
examinations, and the actual comparison of speciﬁc regions
at the strut level between 2 time points is impractical in the
clinical setting. Overcoming these challenges could help
accurately match and compare speciﬁc regions of struts
between 2 time points and lead to a more accurate risk
Table 2. Optical Coherence Tomographic Findings
Post-stent
Cross-section level analysis
Total cross-sections 6,896
Mean stent CSA, mm2 7.5  1.8
Mean lumen CSA, mm2 7.4  1.8
Stent malapposition
Maximal extra-stent lumen CSA, mm2 1.1 (0.7–1.5)
Maximal malapposed distance, mm 173 (138–292)
Strut level analysis
Total strut number 75,401
Embedded struts, % 1.8 (0.6–6.2)
Malapposed strut, % 2.3 (0.5–5.2)
Follow-up
Cross-section level analysis
Total cross sections 6,682
Mean stent CSA, mm2 7.4  1.8
Mean lumen CSA, mm2 7.0  1.8*
Median neointimal hyperplasia CSA, mm2 0.2 (0.1–0.3)
Cross sections with any uncovered strut, % 61.4 (37.9–81.7)
Cross-sections with a ratio of uncovered
to total strut >0.3, %
21.5 (6.8–49.7)
Stent malapposition
Maximal extra-stent lumen CSA, mm2 0 (0–0.7)*
Maximal malapposed distance, mm 0 (0–81.7)*
Type of stent malapposition
Persistent 5 (6.1)
Resolved 61 (74.4)
Late acquired 6 (7.3)
Strut level analysis
Total struts 73,883
Median neointimal hyperplasia thickness, mm 48 (35–74)
Uncovered struts, % 16.0 (7.4–33.3)
Malapposed strut, % 0 (0–0.7)*
Uncovered and malapposed struts, % 0 (0–0.4)
Values are n, mean  SD, median (interquartile range), or n (%). *p < 0.05: post-stent versus
follow-up.
CSA ¼ cross-sectional area.
Table 3. Percentage of Uncovered Struts According to Status of Post-Stent Stru
Apposed
(% Struts)
Overall, N ¼ 82 16.3 (8.1–31.3) (92.2) 0
Lesions with tissue prolapsed, n ¼ 34 28.1 (14.7–41.6) (91.1) 16.
Lesions without tissue prolapsed, n ¼ 48 13.0 (4.7–23.5) (92.4)
Sirolimus-eluting stent, n ¼ 47 21.1 (10.0–32.9) (92.7) 0
Lesions with tissue prolapsed, n ¼ 23 27.7 (14.8–43.6) (91.4) 17.3
Lesions without tissue prolapsed, n ¼ 24 13.9 (4.1–24.4) (93.8)
Biolimus-eluting stent, n ¼ 35 14.8 (5.7–29.0) (91.4)
Lesions with tissue prolapsed, n ¼ 11 31.4 (13.4–36.6) (90.1) 10.
Lesions without tissue prolapsed, n ¼ 24 10.7 (4.9–21.8) (92.1)
Values are median (interquartile range) unless otherwise indicated. *p < 0.05: sirolimus- versus biolimu
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647assessment of stent thrombosis (10). In this study, we
demonstrate that by using a contour plot OCT analysis, the
serial assessment of speciﬁc regions at the strut level is
practical, and the comprehensive monitoring of stent
strut status between baseline and follow-up provides useful
information about vascular healing status after DES
implantation.
The extent of stent strut coverage is inﬂuenced by a
number of factors, including patient and lesions
characteristics, stent type, and procedural factors (7–11).
The procedural factors can be modiﬁed by using OCT-
guided procedural optimization to improve strut apposition
to the vessel wall leading to a decrease in the extent of un-
covered stent struts. The clinical signiﬁcance of apposed
versus embedded struts after intervention has not been
sufﬁciently evaluated. One recent report indicated that
embedded struts did not correlate with stent strut coverage
and neointimal formation (20). It should be noted that the
meticulous serial tracking between post-intervention and
follow-up of each individual strut at the strut level was not
performed in this study (20). Our study demonstrates the
beneﬁcial effects of strut coverage in embedded struts versus
apposed or malapposed struts (the median percentage of
uncovered struts was 0% in embedded vs. 16.3% in apposed
or 26.8% in malapposed struts, p < 0.001 for all pairwise
comparisons). In addition, we found that the percentage of
uncovered struts in the presence or absence of tissue prolapse
within the stent was signiﬁcantly different in the subgroup of
embedded struts. In cases without prolapse, embedded struts
were all covered (100%) versus those with tissue prolapse
(76.8%, p < 0.01). This difference might be explained by
the nature of prolapsed tissue within the stent. Although we
cannot clearly deﬁne the characteristics of the prolapsed
tissue (because pre-intervention OCT was not performed),
we speculate that the prolapsed tissue might be throm-
bus based on post-intervention OCT images. Thrombus
compression/displacement by the stent strut occurred
during the coronary intervention procedure, and both thets
Embedded
(% Struts)
Malapposed
(% Struts)
p Value
Apposed vs. Embedded;
Apposed vs. Malapposed
(0–11.4) (4.3) 26.8 (0–56.3) (3.5) <0.001; <0.001
5 (7.4–33.9) (5.8) 50.0 (5.6–76.8) (3.1) 0.177; 0.002
0 (0–0) (3.6) 21.1 (0–39.2) (4.0) <0.001; 0.004
(0–17.3)* (4.4) 29.2 (0–58.3) (2.9) 0.018; 0.010
(9.8–58.3)* (5.6) 53.9 (3.7–75.0) (3.0) 0.515; 0.028
0 (0–0) (3.4) 8.9 (0–35.8) (2.8) 0.006; 0.166
0 (0–3.3) (4.2) 25.0 (0–50.0) (4.4) 0.002; <0.001
0 (3.3–20.0) (6.3) 45.2 (17.4–84.4) (3.6) 0.136; 0.017
0 (0–0) (3.1) 22.9 (0–40.3) (4.8) 0.008; 0.007
s-eluting stent.
Figure 5. Examples of the Typical Effects of Embedded, Apposed, and Malapposed Struts at Post-Intervention on Strut Coverage at 6 Months
Blue, red, and green circles indicate embedded, malapposed, and apposed struts, respectively. Nearly all embedded struts (blue circle) showed complete strut
coverage at 6 months (A). Apposed struts (green circle) were uncovered in some proportion (A) and covered in the other proportion at 6 months (B). However,
many malapposed struts (red circle) were not covered without any gap between the strut and the vessel walls at 6 months (A and B).
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648abluminal and luminal thrombi were generally resolved by
the time of the follow-up in the embedded struts (21). Based
on these ﬁndings, we assert that optimizing stent apposition
by using OCT guidance leads to improvements in the stent
strut coverage early after DES implantation. When early
strut coverage is accurately assessed in selected patients with
coronary artery disease, this information can be used to
determine the appropriate treatment strategy, leading to ashorter duration of dual antiplatelet therapy after DES
implantation. Recent studies reported that the degree of
OCT-assessed stent strut coverage may be associated with
future cardiac events (3,22). However, there remains a
concern that stent optimization for embedding the stent
struts into the vessel wall may increase myocardial or
arterial injury. The need for further studies is, therefore,
warranted.
Figure 6. Comparison of Contour Plots Between Sirolimus-Eluting Stent and Biolimus-Eluting Stent
Both stents have a similar distribution of strut apposition post-intervention, but a different pattern of strut coverage and malapposition (greater uncovered and
malapposed struts in the sirolimus-eluting stent [A] than in the biolimus-eluting stent [B]) was observed at the 6-month follow-up.
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649Previous IVUS studies reported favorable long-term
clinical outcomes of acute stent malapposition after DES
implantation (23,24). However, the exact mechanisms to
explain these favorable outcomes remain unexplained. In the
present study, using contour plot analysis we show that 95%
of struts classiﬁed as malapposed after the procedure were
classiﬁed as resolved at follow-up. These ﬁndings may
partly explain the favorable long-term clinical outcomes ofacute stent malapposition after DES implantation. How-
ever, acute malapposed struts are still associated with a
greater incidence of uncovered struts, despite our data. A
previous OCT study examining sirolimus-eluting stents
suggested that strut coverage at 6 months may be delayed
in post-intervention malapposed struts compared with
strut coverage in post-intervention apposed struts (the rate
of uncovered strut: 65% in malapposed vs. 9% in apposed
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650strut post-intervention) (25). Another OCT study similar-
ly reported a higher incidence of uncovered struts in mal-
apposed struts after DES implantation (72.6%) (10). In
this study, the median percentage of uncovered struts
was also greater in malapposed struts (26.8%) than in
apposed struts (16.3%). The discrepancy between favorable
long-term clinical outcomes and the increased rate of un-
covered struts in acute stent malapposition requires fur-
ther investigation. The subsequent clinical outcomes and
status of uncovered struts in acute stent malapposition
may be affected by the initial clinical presentation, un-
derlying plaque characteristics, types of DES used, and
the duration of dual antiplatelet therapy. A proper study
design and implementation will help alleviate these
complications.
Study limitations. It should be noted that the OCT cross
sections contain artifacts such as guidewire shadowing,
nonuniform rotational distortion of mechanical catheter
systems, displacement of catheter position inducing sun-
ﬂower artifacts, and motion artifacts caused by cardiac dy-
namics. Therefore, signiﬁcant motion effects may limit this
assessment of coregistration by calculating arc length values.
The association between plaque characteristics at pre-inter-
vention and follow-up was not evaluated in this study. The
current OCT system cannot detect endothelial cells and is
limited for the evaluation of true endothelialization.
Furthermore, the differentiation of normal neointimal tissue
from ﬁbrin or thrombus over the stent struts is not possible.
This study could not adequately evaluate the impact of
contour plot analysis on clinical outcomes because of the
relatively small population and proportion of embedded
struts. Two types of DESs were used. From a practical
standpoint, an automated system with instantaneous image
interpretation should be required for clinical feasibility. This
study was performed at the strut level. However, there was a
possibility that the healing pattern might be different at the
patient or stent level. Finally, although statistical analysis in
this study did not completely solve the problems of clus-
tering of the OCT data, the impact on the ﬁnal results was
minimal.
Conclusions
We demonstrate a new approach to assess the status of DES
struts between different time points. Our study indicates
that optimization of strut apposition under OCT guidance
may contribute to the improvement of early strut coverage
after DES implantation.
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